Skip to main content

Table 2 Results of global and subgroup analysis

From: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

Subgroup defined by Patient number   Antibody ch14.18
group
Maintenance chemotherapy
group
No consolidation
group
Log-rank
p-value
All patients 344 5yEFS 45.2 ± 3.9% 34.1 ± 4.8% 33.3 ± 5.7% .098
   5yOS 55.8 ± 3.9% 42.2 ± 5.0% 39.1 ± 5.9% .019
   9yEFS 40.9 ± 3.8% 31.0 ± 4.7% 31.8 ± 5.6% .098
   9yOS 45.8 ± 4.0% 33.9 ± 4.8% 34.6 ± 5.7% .019
With ASCT 145 5yEFS 50.5 ± 4.9%   38.1 ± 7.5% .241
   5yOS 58.3 ± 4.9%   45.2 ± 7.7% .152
   9yEFS 44.5 ± 4.9%   38.1 ± 7.5% .241
   9yOS 47.0 ± 5.0%   40.5 ± 7.6% .152
No ASCT 189 5yEFS 36.5 ± 6.1% 34.1 ± 4.8% 25.9 ± 8.4% .133
   5yOS 51.9 ± 6.3% 42.2 ± 5.0% 29.6 ± 8.8% .094
   9yEFS 34.9 ± 6.0% 31.0 ± 4.7% 21.6 ± 8.1% .133
   9yOS 43.9 ± 6.5% 33.9 ± 4.8% 25.4 ± 8.5% .094
NB90 177 5yEFS 48.0 ± 10% 34.1 ± 4.8% 37.7 ± 6.7% .300
   5yOS 52.0 ± 10% 42.2 ± 5.0% 41.5 ± 6.8% .250
   9yEFS 44.0 ± 9.9% 31.0 ± 4.7% 33.6 ± 6.5% .300
   9yOS 48.0 ± 10.0% 33.9 ± 4.8% 37.6 ± 6.7% .250
NB97 157 5yEFS 44.7 ± 4.2%   18.8 ± 9.8% .067
   5yOS 56.5 ± 4.2%   31.3 ± 11.6% .050
   9yEFS 40.3 ± 4.1%   18.8 ± 9.8% .067
   9yOS 45.3 ± 4.3%   23.4 ± 11.0% .050
NB90 maintenance and NB97 ASCT+ch14.18 patients 177 5yEFS 51.3 ± 5.7% 34.1 ± 4.8%   .106
   5yOS 60.3 ± 5.5% 42.2 ± 5.0%   .035
   9yEFS 44.7 ± 5.6% 31.0 ± 4.7%   .106
   9yOS 46.6 ± 5.7% 33.9 ± 4.8%   .035
MYCN not amplified 214 5yEFS 48.4 ± 4.5% 37.0 ± 6.5% 35.3 ± 8.2% .166
   5yOS 61.9 ± 4.4% 47.8 ± 6.5% 44.1 ± 8.5% .041
   9yEFS 45.2 ± 4.5% 31.4 ± 6.3% 35.3 ± 8.2% .166
   9yOS 52.0 ± 4.6% 34.9 ± 6.4% 38.0 ± 8.4% .041
MYCN amplified 69 5yEFS 34.2 ± 7.7% 20.0 ± 10.3% 31.3 ± 11.6% .997
   5yOS 36.8 ± 7.8% 26.7 ± 11.4% 31.3 ± 11.6% .902
   9yEFS 25.5 ± 7.2% 20.0 ± 10.3% 31.3 ± 11.6% .997
   9yOS 24.9 ± 7.2% 20.0 ± 10.3% 31.3 ± 11.6% .902
CR/VGPR after induction 267 5yEFS 47.0 ± 4.3% 34.4 ± 5.3% 36.5 ± 6.7% .185
   5yOS 58.2 ± 4.3% 37.9 ± 5.4% 42.3 ± 6.9% .032
   9yEFS 41.7 ± 4.3% 30.5 ± 5.2% 34.5 ± 6.6% .185
   9yOS 45.8 ± 4.4% 32.8 ± 5.3% 36.3 ± 6.7% .032
CR after induction 166 5yEFS 54.9 ± 5.5 % 40.5 ± 7.1 % 48.6 ± 8.4 % .392
   5yOS 62.2 ± 5.4 % 46.4 ± 7.2 % 57.1 ± 8.4 % .218
   9yEFS 49.8 ± 5.5% 36.1 ± 6.9% 45.7 ± 8.4% .392
   9yOS 51.6 ± 5.6% 37.8 ± 7.0% 48.6 ± 8.4% .218
PR after induction 60 5yEFS 37.0 ± 9.3% 29.4 ± 11.1% 25.0 ± 10.8% .644
   5yOS 46.9 ± 9.8% 58.8 ± 11.9% 31.3 ± 11.6% .632
   9yEFS 37.0 ± 9.3% 29.4 ± 11.1% 25.0 ± 10.8% .644
   9yOS 46.9 ± 9.8% 35.3 ± 11.6% 31.3 ± 11.6% .632
No residual bone marrow involvement after induction 316 5yEFS 46.8 ± 4.0 % 36.0 ± 5.0 % 33.8 ± 5.7 % .122
   5yOS 57.0 ± 4.0 % 43.4 ± 5.1 % 39.7 ± 5.9 % .033
   9yEFS 42.1 ± 4.0% 32.6 ± 4.9% 32.2 ± 5.6% .122
   9yOS 46.8 ± 4.1% 35.7 ± 5.0% 35.1 ± 5.8% .033
\